← Back to Search

Educational Program

HALT-AD for Dementia (HALT-AD Trial)

N/A
Waitlist Available
Led By Sarah Banks, PhD, ABPP-CN
Research Sponsored by Alzheimer's Disease Cooperative Study (ADCS)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Signed informed consent must be obtained and documented (from the participant).
Sufficient proficiency in English or Spanish to undergo clinical assessment and participate in an online educational program.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months
Awards & highlights

HALT-AD Trial Summary

This trial will focus on at least three educational courses on topics related to dementia and lifestyle risk factors, sleep and diet. It may also include a fourth educational course on social connectivity and loneliness. This study will help inform the development of the second program's prototype, expected to benefit from the initial pilot to become more user-friendly, effective and accessible to the target audience.

Eligible Conditions
  • Dementia
  • Alzheimer's Disease
  • Dementia Prevention

HALT-AD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are able to participate in an online educational program.

HALT-AD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acceptability Survey- Users' acceptability of the HALT-AD program content
FOCUS Group discussion- Qualitative evaluation of the HALT-AD program content
Qualitative evaluation of participant responses during the focus group discussion groups
+4 more
Secondary outcome measures
Change from baseline in knowledge on the HALT-AD knowledge assessment survey at 4 months
Change from baseline in lifestyle risk on the HALT-AD lifestyle risk assessment survey at 4 months
Change from baseline in self-efficacy on the New General Self-Efficacy Scale (NGSE) at 4 months.

HALT-AD Trial Design

1Treatment groups
Experimental Treatment
Group I: HALT-ADExperimental Treatment1 Intervention
This arm includes cognitively normal midlife and older-adult participants with the following inclusion criteria: Signed informed consent must be obtained and documented (from the participant) Sufficient proficiency in English or Spanish to undergo clinical assessment and participate Ages 50-85 Montreal Cognitive Assessment-Telephone/Blind Version (T-MoCA) score ≥18/22 Technical ability to participate Sufficient vision and hearing to participate Ability to sit comfortably for a period of at least 30 minutes A total of 20 participants will be enrolled at UCSD 10 will complete the English version 10 will complete the Spanish version Aim is to recruit 50% women and to enroll a diverse participant sample across varied age ranges within both language groups.

Find a Location

Who is running the clinical trial?

Alzheimer's Disease Cooperative Study (ADCS)Lead Sponsor
24 Previous Clinical Trials
6,731 Total Patients Enrolled
Sarah Banks, PhD, ABPP-CNPrincipal InvestigatorAlzheimer's Disease Cooperative Study (ADCS)
Howard Feldman, MDCM FRCP(C)Study DirectorAlzheimer's Disease Cooperative Study (ADCS)
1 Previous Clinical Trials
296 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What site did they apply to?
Alzheimer's Disease Cooperative Study (ADCS)
What portion of applicants met pre-screening criteria?
Met criteria
~7 spots leftby Mar 2025